New warning for asthma medication


Warning
Health professionals are being urged to “look out” for neuropsychiatric reactions in patients using montelukast  A new boxed warning about potentially serious neuropsychiatric events is being added to the safety information for prescription asthma and allergic rhinitis medication, montelukast.  The safety update follows an investigation by the Therapeutic Goods Administration (TGA), which was conducted after

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Boost for aged care medication safety
Next Chemist Warehouse franchisees in line for post-merger windfall